Denver Internal Medicine Group

Robert J. Doolan, MD,

Denver Internal Medicine Group 360 South Garfield Suite 550 Denver, CO 80209 Phone: 303-333-5456 Fax: 303-320-6910 Email: [email protected]

Date of Birth: November 9, 1970

Graduate Education:

1999.2002 Resident in Internal Medicine University of Colorado Health Sciences Center 4200 East 9th Avenue Denver, CO

1995.1999 Doctor of Medicine Wayne State University School of Medicine 540 East Canfield Detroit, MI 48201

Undergraduate Education:

1988.1992 B.S. Electrical Engineering University of Michigan- Ann Arbor

Board Certification:

American Board of Internal Medicine Initial certification 2002-2012 Recertification 2012-2022

Employment: 2003-Present Mountain View Clinical Research Inc, Principal and Sub Investigator Clinical Research, Denver, CO 2002-2011 Select Specialty Hospital, Hospitalist Denver, CO 2011-2013 Spalding Rehabilitaion Hospital, Hospitalist Aurora, CO 2002-Present Denver Internal Medicine Group, Internal Medicine, Denver, Co 2014-2015 Community Recovery, Colorado Medical Director 1993.1995 Developmental Engineer, Lear Seating Corporation Southfield, MI 1992.1993 Test Engineer, Ford Motor Company Dearborn, MI

Medical Boards: 2011-2013 Spalding Rehabilitation Hospital, Member at Large - Medical Executive Committee Aurora, CO 2011-2013 Spalding Rehabilitation Hospital, Chair Pharmacy and Therapeutics Committee Aurora, CO 2011-Present Key/SMPC Board Member Denver, CO 2012-2013 PHP Pioneer ACO Advisory Board Member Denver, CO 2014-Present PHP Education Committee SMPC representative

Lecture:

Lifting The Hex – The Role of Curanderos ACP-ASIM Colorado Associates’ Scientific Meeting June 5, 2001

Memberships:

American College of Physicians Colorado Medical Society Denver Medical Society

Research Experience:

Sub- Investigator: A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 vs. Placebo in Subjects with Active Rheumatoid Arthritis on Background DMARDS Who Have Failed Anti-TNF Therapy.

Sub- Investigator: A Phase III, Multi-Center, Randomized, Double-Blind Placebo-Controlled Clinical Use Study to Evaluate the Safety and Tolerability of BMS-188667 Administered Intravenously to Subjects with Active Rheumatoid Arthritis (RA) With or Without Medical Co- Morbidities Receiving Disease Modifying Anti- Rheumatic Drugs (DMARDS) and/or Biologics Approved for RA.

Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Determine the Efficacy and Safety of The Buprenorphine Transdermal Delivery System (BTDS) in Subjects with Moderate To Severe Osteoarthritic Pain of the Hip or Knee. Principal Investigator: A Phase III, Randomized, Three-Arm, Double-Blind, Active Controlled, Parallel Group, Multicenter Trial to Evaluate the Safety and Efficacy of Muraglitazar in Combination with Metformin Compared to Glimepiride in Combination with Metformin in subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Therapy Alone.

Principal Investigator: A 4-Week Randomized Double-Blind, Placebo-and Active Controlled, Parallel- group, Forced-titration Study Comparing Efficacy and Safety of Ascending Doses of CG5503 Prolonged Release Up to 233mg BID and Oxycodone Prolonged releases up to 20 mg BID to Placebo Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee. Phase IIB

Principal Investagator: A Multicenter, Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control with Diet and Exercise

Sub- Investigator: A Multicenter, Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Principal Investigator: A Multicenter, Randomized, Double –Blind, Placebo Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) In Combination with Thiasolidinedone Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiasolidinedone Therapy Alone

Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Glyburide in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Glyburide Alone

Principal Investigator: A Double Blind, Placebo Controlled, Randomized, Parallel Group Study of the On-Demand for Up to 7 Episodes Over a Period of 6 Weeks for the Treatment of Occasional Episodes of Self-Reported Abdominal Pain, Cramping, and Discomfort in an OTC-Like Study Population

Principal Investigator: A multi-center, randomized, open-label, active controlled, Parallel arm study to compare the efficacy of 12 weeks of treatment with Vildagliptin 100 mg, qd to thiazolidinedione (TZD) as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy in a community-based practice setting. Principal Investigator: Abbott Laboratories, “A Phase 3, Open-label Period Followed by a Randomized, Double-blind, Placebo-controlled Study of the Analgesic Efficacy and Safety of Extended-release Hydrocodone/Acetaminophen (Vicodin CR) Compared to Placebo in Subjects with Chronic Low Back Pain”

Principal Investigator: A Double Blind, Placebo Controlled, Randomized, Parallel Group Study of the Efficacy and Safety of Oral Doses of 20 mg Hyoscine Butyllbromide when Used and Based on a Patients Decision to Self Medicate for Up to 7 Episodes Over a Period of 6 Weeks for the Treatment of Occasional Episodes of Self-Reported Abdominal Pain or Discomfort Associated with Cramping in an OTC-Like Study Population

Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Efficacy Study of Kadian NT ( Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects with Moderate to severe Chronic Pain Due to Osteoarthritis of the Hip or Knee

Principal Investigator: A Randomized, Double-Blind, Active-Control, Parallel Group, 90-Day Safety Study of CG5503 Immediate Release (IR) or Oxycodone IR in Subjects With Chronic Pain From Low Back Pain (LBP) or Osteoarthritis (OA) of the Hip or Knee

Principal Investigator: A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Asses Glycemic Control with Rimonabant in Comparison with Glimepiride over 1 Year in overweight/Obese Type 2 Diabetic Patients Not Adequately Controlled with Metformin

Principal Investigator: A Long-Term, Randomized, Double-Blind, Parallel- Group, Placebo-Controlled, Radiographic Study to Investigate the Safety and Efficacy of Orally Administered SD-6010 In Subjects with Symptomatic Osteoarthritis of the Knee

Principal Investigator: A 16-Week, Phase 1, Multicenter, Doulble-Blind, Randomized, Naproxen, and Ibuprofen-controlled, Parallel-Group Pharmacological Study to Assess the Effect of Naproxcinod (375 mg and 750 mg, bid) and to Ibuprofen (600 mg, tid) on Arterial Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Osteoarthritis Patients with Controlled Essential Hypertension

Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotherapy in Subjects with Type 2 Diabetes who Have Inadequate Glycemic Control with Diet and Exercise Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) In Combination with Thiazolidinedione Therapy Alone

Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate HGlycemic Controlwith Diet and Exercise

Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapaliflozin in Combination with Thiazolidinedione Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Controlon Thiazolidinedione Alone